NEWS
DEXTER® Robotic Surgery System to Memorial Hermann Health System
Distalmotion announces that it completed the first US sale and delivery of the DEXTER Robotic Surgery System to Memorial Hermann Health System in Houston, Texas in early February. This milestone marks a significant step toward expanding access to robotic surgery in the United States. Distalmotion, a MedTech company with more than 1,500 surgical cases completed … Read more
HAYA Therapeutics Raises $65 Million in Series A Funding to Deliver Precision RNA-Guided Medicines for Chronic and Age-Related Diseases
Series A round led by Sofinnova Partners and Earlybird Venture Capital with syndicate including Eli Lilly and Company Funds to advance clinical development of heart failure lead candidate and expand platform targeting the regulatory genome LAUSANNE, Switzerland and SAN DIEGO, USA – May 8, 2025 – HAYA Therapeutics, SA, a biotechnology company pioneering precision RNA-guided regulatory … Read more
Distalmotion Advances US Expansion of its DEXTER® Surgical Robot with Clinical Milestones and System Enhancements
Distalmotion, the global MedTech company empowering access to the benefits of robotic surgery, progresses on the path to expand its US footprint with the completion of cholecystectomy and benign hysterectomy clinical trials – to support 510(k) pre-market submissions for additional indications – and product enhancements to further increase procedural fluidity and wristed instrument dexterity. The … Read more
Patient Centric Drug Development Panel at Longwood Healthcare Leaders
Joining an esteemed panel at the Longwood Fund Healthcare Leaders meeting, Lynn Durham discusses the need for patient centric drug development, specifically in the context of neurodevelopmental disorders https://stalicla.com/assets/new/img/news/articles/Longwood_Fund_annual_meeting_horizontal.jpg See full text Follow us on
DEXTER® Robotic Surgery System by the First Ambulatory Surgery Center in the US
Two patients were treated for inguinal hernia repair using Distalmotion’s Dexter® Robotic Surgery System within 30 days of FDA De Novo Northtowns Ambulatory Surgery Center (ASC), a joint venture between Buffalo surgeons and Kaleida Health Ventures, has chosen Distalmotion’s DEXTER® Robotic Surgery System as its outpatient surgical robot of choice, marking a major milestone in … Read more
Dexter® Robotic Surgery System in the Outpatient Setting
Two patients were treated for inguinal hernia repair using Distalmotion’s Dexter® Robotic Surgery System within 30 days of FDA De Novo marketing authorization. Less than 30 days after receiving FDA De Novo marketing authorization, Distalmotion’s Dexter Robotic Surgery System has successfully treated the first US patients in an outpatient setting. Two adult inguinal hernia repairs … Read more
HAYA Therapeutics Awarded Innosuisse Certificate for Sustainable Growth and Funding to Advance Treatment for Aggressive Solid Tumors
Former Exscientia executive who helped build the company and facilitate its merger with Recursion Pharmaceuticals joins to accelerate HAYA’s Non-dilutive funding of 1.5M CHF will be used to develop a novel therapy targeting cancer-associated fibroblast-specific long non-coding RNA (lncRNA) LAUSANNE, Switzerland and SAN DIEGO, USA – Feb. 12, 2025 – HAYA Therapeutics, SA, a biotechnology company … Read more
Putting innovation at the heart of RNA-based therapeutics
Working towards a crucial breakthrough in the way we treat disease: HAYA Therapeutics aims to revolutionise patients treatments by focusing on Dark Genome-derived RNAs, now recognised as the ‹Regulatory Genome› RNAs. Thanks to its innovative approach, the company has attracted the attention of American pharmaceutical giant Eli Lilly. HAYA Therapeutics, which is supported by Innosuisse, is capitalising … Read more
First Patients in U.S. Treated with Distalmotion’s Dexter Surgical Robot in the Outpatient Setting
October 28 , 2024 Distalmotion’s Dexter Surgical Robot opens an entire new era for soft tissue robotics in the outpatient setting and ambulatory surgery centers that will have immediate benefit for patients. Distalmotion has been granted De Novo approval by the U.S. Food and Drug Administration (FDA) to market the Dexter Surgical Robot for … Read more
EP #453 – Samir Ounzain: Unlocking the Power of the Dark Genome
This episode was sponsored by smzh, your independent go-to partner in all matters relating to finance. About Samir Ounzain: Samir Ounzain is the co-founder and CEO of HAYA Therapeutics, a precision medicines company targeting the regulatory genome for cardiovascular diseases, fibrosis and cancer. He holds a PhD from the University of Leicester and was previously a researcher at … Read more
